RNAs may help identify stage II colon cancer patients who could benefit from chemotherapy following surgery

The decision to treat patients with stage II colon cancer with adjuvant chemotherapy remains controversial. Therefore, there is an urgent need to identify reliable prognostic biomarkers that may be used to identify which patients would benefit from chemotherapy following surgery. In a study investigators have assessed the biomarker potential of RNAs in stage II colon cancer. Their findings appear in The American Journal of Pathology.

​Medical Xpress – latest medical and health news stories

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *